Please assess the completion status of the following clinical trial:

Trial Title: Mesenchymal Stem Cell Transplantation in MS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Inflammatory forms of MS~   1. Relapsing-remitting MS (RRMS) patients~  2. Secondary progressive MS (SPMS) patients with continued relapses~  3. Primary progressive MS (PPMS) patients with enhancing MRI lesions and positive CSF (oligoclonal banding)~2. Age 18-50 years~3. Disease duration \>= 2 and \>= 10 years~4. EDSS 3.0 - 6.5~5. Progression, continued relapses or worsening MRI after at least a year of attempted therapy evidenced by:~   1. Increase of \>= 1 EDSS point (if baseline EDSS \<= 5.0) or 0.5 EDSS points (if baseline EDSS \>= 5.5), or quantifiable, objective evidence of equivalent progression~  2. \>= 1 moderate-severe relapses in past 18 months~  3. \>= 1 Gadolinium enhancing lesions (double or triple dose Gadolinium)~  4. \>= 1 new T2 lesion~  5. For PPMS only, \>= 1 Gadolinium enhancing lesions~6. Has given informed consent to participate in the study.~Exclusion Criteria:~1. SPMS without ongoing relapses~2. PPMS without positive CSF or Gadolinium enhancing lesions~3. \<= 3 months since treatment with any immunosuppressive therapy~4. \<=1 month since last treatment with interferon-B or glatiramer acetate~5. Corticosteroid treatment \<= 30 days~6. Relapse \<= 60 days~7. History of cancer or clinical or laboratory results indicative of severe systemic diseases, including infection for HIV, Hepatitis B or C~8. Any metallic or electronic device that precludes from undergoing MRI~9. Pregnancy or lactation~10. Current treatment with an investigational therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- autologous mesenchymal stem cell (Type: EXPERIMENTAL): A single infusion of up to 2 million cells per Kg of autologous mesenchymal stem cells vs suspension media. The treatment will be reversed at 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).